Trial · NCT01190813
Results by group204
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 204
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | 10-14 letters worse | 0 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | 10-14 letters worse | 0 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | 5-9 letters worse | 2 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | 5-9 letters worse | 1 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | within 4 letters | 35 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | within 4 letters | 23 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | 5-9 letters better | 36 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | 5-9 letters better | 19 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | 10-14 letters better | 10 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | 10-14 letters better | 1 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Levodopa/Carbidopa | >= 15 letters better | 3 | participants | |
| Distribution of Amblyopic Eye Visual Acuity Change From Baseline | Placebo | >= 15 letters better | 1 | participants | |
| Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks | Levodopa/Carbidopa | 13 | participants | ||
| Amblyopic Eye Visual Acuity Improvement Treatment Group Comparison at 18 Weeks | Placebo | 2 | participants | ||
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Levodopa/Carbidopa | 20/25 (78-82 letters) | 0 | participants | |
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Placebo | 20/25 (78-82 letters) | 0 | participants | |
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Levodopa/Carbidopa | 20/32 (73-77 letters) | 5 | participants | |
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Placebo | 20/32 (73-77 letters) | 1 | participants | |
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Levodopa/Carbidopa | 20/40 (68-72 letters) | 7 | participants | |
| Distribution of Amblyopic Eye Visual Acuity at 18 Weeks | Placebo | 20/40 (68-72 letters) | 6 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01190813/results